J&J forecast to dominate BiTE market
Bispecific T-cell engagers (BiTEs) are a rapidly emerging new therapeutic. By 2030, this drug category is forecast to generate $20.6bn,…
Bispecific T-cell engagers (BiTEs) are a rapidly emerging new therapeutic. By 2030, this drug category is forecast to generate $20.6bn,…
Sionna Therapeutics, a biopharmaceutical company dedicated to advancing treatments for cystic fibrosis (CF), has significantly strengthened its position in the…
AbbVie has maintained a strong position within the immunology space for the past few years, largely due to the success…
On 29 June 2024, during an e-presentation session on the topic of movement disorders at the 10th Congress of the…
At the 10th Congress of the European Academy of Neurology (EAN) 2024, three papers were presented on the efficacy of…
Eli Lilly announced on 2 July 2024 that the US Food and Drug Administration (FDA) has approved its anti-amyloid beta…
On 30 June 2024, at the tenth Congress of the European Academy of Neurology (EAN) 2024, during an e-presentation session…
On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide, for $35.1m. Avexitide…
The FDA has approved Verona Pharma’s first-in-class dual phosphodiesterase 3/4 inhibitor, Ohtuvayre (ensifentrine), for the US market. The asset is…
Asthma is a chronic immunological pulmonary disorder characterized by restriction of the airways, resulting in recurrent episodes of coughing, wheezing,…